UCB awards Chair in IBS management
Belgian drugmaker UCB has announced the creation of the Chair in Management of Inflammatory Bowel Disease to support the research of professors Severine Vermeire and Paul Rutgeerts of the division of Gastroenterology of the university hospital at the Katholieke Universiteit Leuven. The research concerns the mechanisms of action of biological therapies in IBD and predictive factors for outcome.
UCB's sponsorship of this respected academic chair at an institution recognized for its leadership in the study and treatment of gastroenterology is part of the firm's ongoing commitment to supporting research into inflammatory disease.
The company submitted the license applications for its first biologic, Cimzia (certolizumab pegol) for the treatment of Crohn's disease (an inflammatory bowel disease) with the regulatory authorities in both the USA and Europe earlier this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze